This could make lots of perception. But will the EPIC Act pass? My anxiety is that this will likely be viewed as being a give-back to the biopharma industry equally as selling price controls are starting to just take result thereby causing rejection of the Invoice. A bigger worry could be that Congress would take care of the “small molecule penal